HALOZYME THERAPEUTICS INC (HALO) Stock Price, Forecast & Analysis
USA - NASDAQ:HALO - US40637H1095 - Common Stock
HALO Key Statistics, Chart & Performance
The current stock price of HALO is 65.19 USD. In the past month the price decreased by -5.49%. In the past year, price increased by 14.07%.
HALO Latest News, Press Relases and Analysis
HALO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.07 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 894.2 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.04 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About HALO
Company Profile
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Company Info
HALOZYME THERAPEUTICS INC
12390 El Camino Real
San Diego CALIFORNIA 92121-1345 US
CEO: Helen I. Torley
Employees: 350
Phone: 18587948889
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you describe the business of HALOZYME THERAPEUTICS INC?
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
What is the current price of HALO stock?
The current stock price of HALO is 65.19 USD. The price increased by 0.87% in the last trading session.
What is the dividend status of HALOZYME THERAPEUTICS INC?
HALO does not pay a dividend.
What is the ChartMill rating of HALOZYME THERAPEUTICS INC stock?
HALO has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
What is HALOZYME THERAPEUTICS INC worth?
HALOZYME THERAPEUTICS INC (HALO) has a market capitalization of 7.63B USD. This makes HALO a Mid Cap stock.
Who owns HALOZYME THERAPEUTICS INC?
You can find the ownership structure of HALOZYME THERAPEUTICS INC (HALO) on the Ownership tab.
What is the Short Interest ratio of HALOZYME THERAPEUTICS INC (HALO) stock?
The outstanding short interest for HALOZYME THERAPEUTICS INC (HALO) is 9.96% of its float.
HALO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to HALO. When comparing the yearly performance of all stocks, HALO turns out to be only a medium performer in the overall market: it outperformed 68.2% of all stocks.
HALO Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to HALO. HALO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
HALO Financial Highlights
Over the last trailing twelve months HALO reported a non-GAAP Earnings per Share(EPS) of 5.18. The EPS increased by 58.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 47.28% | ||
| ROA | 27.13% | ||
| ROE | 167.48% | ||
| Debt/Equity | 4.54 |
HALO Forecast & Estimates
16 analysts have analysed HALO and the average price target is 77.18 USD. This implies a price increase of 18.39% is expected in the next year compared to the current price of 65.19.
For the next year, analysts expect an EPS growth of 48.46% and a revenue growth 31.48% for HALO